阿仑膦酸钠治疗5年与10年后药物假期的成本效果分析
该成本效果分析基于个体水平状态转移微模拟模型,比较美国绝经后骨质疏松女性(股骨颈BMD T值-2.5至-3.5)接受阿仑膦酸钠5年/5年假期、10年/5年假期或不治疗三种策略。结果显示50、60、70岁起始治疗者5/5策略更有效且成本更低,80岁者10/5策略占优。
要点
- 50-70岁绝经后骨质疏松女性,阿仑膦酸钠治疗5年后药物假期更有效且成本更低。
- 80岁起始治疗者,阿仑膦酸钠治疗10年后药物假期更具成本效果。
- 若假设治疗6-10年非椎体骨折相对风险更低,10/5策略在更年轻年龄也变为最具成本效果。
核心结论
- 对于50-70岁绝经后骨质疏松女性,阿仑膦酸钠治疗5年后药物假期可能获益。
- 对于80岁女性,阿仑膦酸钠治疗10年后药物假期可能获益。
研究设计与样本
- 研究采用个体水平状态转移微模拟模型,比较三种策略:阿仑膦酸钠5年/5年假期、10年/5年假期和不治疗。
- 研究对象为美国绝经后骨质疏松女性,基线股骨颈BMD T值在-2.5至-3.5之间。
主要发现
- 基础案例分析显示,50、60、70岁起始治疗者中,5/5策略优于10/5策略和不治疗(更有效且成本更低)。
- 80岁起始治疗者中,10/5策略占优。
- 当假设治疗6-10年非椎体骨折相对风险低于基础假设时,10/5策略在更年轻起始年龄也变为最具成本效果。
- 概率敏感性分析支持基础案例发现:50、60、70岁倾向5/5策略,80岁倾向10/5策略,但存在不确定性。
关键数值与推荐
- 基线股骨颈BMD T值范围为-2.5至-3.5。
- 比较的策略包括:阿仑膦酸钠5年治疗后5年药物假期(5/5)、10年治疗后5年药物假期(10/5)和不治疗。
- 分析起始治疗年龄为50、60、70和80岁。
临床怎么用
- 对于50-70岁绝经后骨质疏松女性,可考虑阿仑膦酸钠治疗5年后进入药物假期。
- 对于80岁女性,可考虑阿仑膦酸钠治疗10年后再进入药物假期。
局限性
- 概率敏感性分析显示结果存在不确定性。
- 成本效果结论受非椎体骨折相对风险假设影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We performed a cost-effectiveness analysis comparing 5 versus 10 years of alendronate treatment prior to 5-year drug holiday for US postmenopausal women with hip BMD T-scores between - 2.5 and - 3.5. We found that for most postmenopausal women 5 years of treatment prior to drug holiday is the more effective and cost-effective option. INTRODUCTION: We performed a cost-effectiveness analysis to compare 5 versus 10 years of alendronate treatment prior to 5-year drug holiday for postmenopausal osteoporotic women. METHODS: We created an individual-level state-transition microsimulation model to compare 3 treatment strategies for US postmenopausal women with osteoporosis and femoral neck BMD T-scores between - 2.5 and - 3.5 at baseline: recurrent periods of 5 years of alendronate followed by 5 years of drug holiday (alendronate 5/5), recurrent periods of 10 years of alendronate followed by 5 years of drug holiday (alendronate 10/5), and no alendronate treatment. RESULTS: Base-case analysis revealed for women initiating treatment at ages 50, 60, and 70, the alendronate 5/5 strategy dominated (was more effective and less costly than) the alendronate 10/5 strategy and no treatment. For women age 80, the alendronate 10/5 strategy dominated. When assuming a lower relative risk of nonvertebral fracture during years 6-10 of alendronate treatment than the base-case assumption, the alendronate 10/5 strategy became the most cost-effective strategy even at younger treatment initiation ages. Probabilistic sensitivity analysis results supported the base-case findings; for treatment initiation ages of 50, 60, and 70, the alendronate 5/5 strategy was favored, whereas for treatment initiation age of 80, the alendronate 10/5 strategy was favored; however, there was uncertainty in these findings. CONCLUSIONS: After 5 years of alendronate treatment, younger postmenopausal women (ages 50-70) with osteoporosis would likely benefit from a drug holiday, whereas older women (age 80) are likely to benefit from treatment for 10 years before a drug holiday.
引用
- Nayak S, Greenspan SL. Cost-effectiveness of five versus ten years of alendronate treatment prior to drug holiday for women with osteoporosis. Osteoporos Int. 2020. PMID: 32020265. doi:10.1007/s00198-019-05258-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。